<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CA857F73-BFBF-4F6F-AE32-2C9A1C481129"><gtr:id>CA857F73-BFBF-4F6F-AE32-2C9A1C481129</gtr:id><gtr:name>Synairgen plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EBF2F028-E935-4594-BEDE-45A732A2EAD0"><gtr:id>EBF2F028-E935-4594-BEDE-45A732A2EAD0</gtr:id><gtr:name>Association of the British Pharmaceutical Industry (ABPI)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Inflammation Infection and Repair</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CA857F73-BFBF-4F6F-AE32-2C9A1C481129"><gtr:id>CA857F73-BFBF-4F6F-AE32-2C9A1C481129</gtr:id><gtr:name>Synairgen plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EBF2F028-E935-4594-BEDE-45A732A2EAD0"><gtr:id>EBF2F028-E935-4594-BEDE-45A732A2EAD0</gtr:id><gtr:name>Association of the British Pharmaceutical Industry (ABPI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D3D3F76B-F553-4E47-8D35-A564C748B364"><gtr:id>D3D3F76B-F553-4E47-8D35-A564C748B364</gtr:id><gtr:firstName>Donna</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E67B7876-605A-42E6-8ACF-7A67048EE1C8"><gtr:id>E67B7876-605A-42E6-8ACF-7A67048EE1C8</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Warner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F70BC32F-8A32-4BAB-BA6D-EC0C4E1E18AF"><gtr:id>F70BC32F-8A32-4BAB-BA6D-EC0C4E1E18AF</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FFADE489-5C2F-4860-A8CC-16981824D4E3"><gtr:id>FFADE489-5C2F-4860-A8CC-16981824D4E3</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Holgate</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501506"><gtr:id>F28F5255-28FD-49D5-8DBC-558B0065C1C7</gtr:id><gtr:title>The molecular basis of impaired innate immunity to virus infection in asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501506</gtr:grantReference><gtr:abstractText>We are investigating the reasons why common cold viruses make asthma symptoms worse. These periods of worsened symptoms (exacerbations) can be severe enough to cause an increase in the need for medications, and may result in hospitalisation and even death. The most common trigger for these serious exacerbations is a virus infection, such as the common cold. Recently, we have made progress in addressing this problem by demonstrating that the cells that line the airways (epithelial cells) which are the primary target for infection by the common cold virus fail to mount an effective anti-viral response if they are derived from an asthmatic donor. This means that cold viruses are able to replicate more efficiently resulting in lingering lower respiratory tract problems. The purpose of our study is to investigate this defect with a view to identifying novel targets for development of new and effective therapies for virus-induced exacerbations of asthma where there is an unmet clinical need. We also propose to examine the anti-viral response of cells from wheezy and asthmatic children because a defective response in early life may explain the link between viral infections and the onset of asthma.</gtr:abstractText><gtr:technicalSummary>Epidemiological studies have linked viral respiratory infection in early life to asthma pathogenesis. Furthermore, the majority of acute asthma exacerbations, especially in children, follow upper respiratory viral infections, of which at least 60% are caused by human rhinoviruses (RV). Despite the increasing frequency of asthma and the associated morbidity, the mechanisms by which RVs may trigger or exacerbate asthma are incompletely understood. Recent studies at the University of Southampton have shown that bronchial epithelial cells (BECs) from asthmatic donors have a defective innate immune response characterized by reduced interferon beta (IFNb) production and reduced apoptosis following infection with RV. These studies provide, for the first time, an explanation for the tendency of asthmatic subjects to have lingering lower respiratory tract problems as a consequence of RV infection. 
Recognizing that exacerbations of asthma represent the most severe aspect of this disease and account for a substantial proportion of the health costs both in children and adults, the purpose of the proposed investigation is to test the hypothesis that the impaired innate anti-viral immune response in epithelial cells from asthmatic subjects is a specific defect involving signalling pathways that recognize viral RNA resulting in failure to activate transcription from the IFNb promoter; we further postulate that this defect is an intrinsic or acquired defect that increases the susceptibility of asthmatic children to RV infection. 
To test our hypotheses, we will investigate: 
a) the immediate response to virus infection by focussing on activation of pathways that recognize dsRNA (TLR3, RIG-1 and PKR) leading to IRF3 activation and transcription of IFNb;
b) the ability of asthmatic epithelial cells to amplify the immediate innate immune response by analyzing autocrine/paracrine stimulation of the type 1 interferon receptor leading to STAT1 activation and transcription of IRF3 and IRF7 leading to sustained expression of type 1 interferons; 
 c) the potential of compounds that modulate interferon production to protect asthmatic epithelial cells against RV infection; 
 d) the susceptibility of bronchial epithelial cells from asthmatic children to RV infection in vitro.

These studies have the potential to identify novel targets for development of new and effective therapies for virus-induced exacerbations of asthma where there is an unmet clinical need. Demonstration of a defective innate immune response in asthmatic or wheezy children, will have implications both for treatment of virally-induced exacerbation of asthma in children, and for disease pathogenesis which is strongly associated with respiratory virus infection in early life.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>649412</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Unit of Respiratory Immunopharmacology Lund</gtr:department><gtr:description>Viral infection in COPD - Lund</gtr:description><gtr:id>941FCDD2-8E93-4171-A9F7-74C74E772AED</gtr:id><gtr:impact>21691053</gtr:impact><gtr:partnerContribution>21691053</gtr:partnerContribution><gtr:piContribution>Training of Dr Uller in epithelial cell culture and experimental infection. 
Upon return to Sweden Dr Uller collaborated with Prof Davies who participated in a study undertaken in Sweden by assting with data interpretation and preparation of the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cincinnati</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Perinatal Institute Cincinnati</gtr:department><gtr:description>Viral infection in cystic fibrosis</gtr:description><gtr:id>EE2A7E5E-50C8-4AA4-B06D-81CE24ADA6CB</gtr:id><gtr:impact>the collaboration has led to generation of microarray data that will facilitate hypothesis generation</gtr:impact><gtr:partnerContribution>The collaboration has enabled microarray analysis of differentiated epithelial cell cultures from normal and CF children following rhinovirus infection. This has generated substantial datasets for bioinformatic analysiss and data mining.</gtr:partnerContribution><gtr:piContribution>We established protocols for growth and differentiation of bronchial epithelial cells from normal</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Synairgen plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BECs</gtr:description><gtr:id>E34B4276-D7E4-44E7-890F-80B86993966E</gtr:id><gtr:impact>PubMed ID 19265144</gtr:impact><gtr:partnerContribution>Provision of primary airway cells for some of our research work.</gtr:partnerContribution><gtr:piContribution>studies of the responses of bronchial fibroblasts to rhinovirus infection.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Association of the British Pharmaceutical Industry (ABPI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>COPDMAP</gtr:description><gtr:id>171CB24B-18EB-4238-8230-EECEAD0F1902</gtr:id><gtr:impact>Investigation of innate immune dysfunction of airway epithelial cells and the association with responses to oxidative stress.</gtr:impact><gtr:partnerContribution>Investigation of the innate immune responses of BECs from COPD patients to rhinovirus infection</gtr:partnerContribution><gtr:piContribution>Member of workpage 3</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>lab visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>260A0811-972C-43EC-B706-BE0E63ED4BAA</gtr:id><gtr:impact>small groups of visitors visited the lab to learn about our research

help local charity fund raising</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2009,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>147000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>COPD MAP collaborative grant year 1</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001367/1</gtr:fundingRef><gtr:id>CE46275B-7F27-4EA7-BDE3-5A1629C68065</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2560000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A Life Course Approach To Investigating Asthma Pathogenesis And Progression</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0900453</gtr:fundingRef><gtr:id>1A327F28-15DC-442A-939B-F8F55BDFC439</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Foundation Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:fundingRef>09/053</gtr:fundingRef><gtr:id>74F09BEF-27C5-456A-93CA-1748922103E1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1095618</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>COPDMAP continuation</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001367/1</gtr:fundingRef><gtr:id>80881D2C-49A5-4374-85C8-29843E49FBD4</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49693</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Foundation Grant</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:fundingRef>10/060</gtr:fundingRef><gtr:id>D02F9A54-62C3-4EE7-AFF9-80C2822BEDD7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>299000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R's Project Grant</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>G0700636/1</gtr:fundingRef><gtr:id>54E4774C-63E2-411B-A597-46AF4474C0D7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1107763</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC EP/G061696/1 Silicon Nanowire Arrays for Viral Infection Markers (NanoTechnology Grand Challenge in Healthcare)</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G061696/1</gtr:fundingRef><gtr:id>0FFAFD2A-5D54-4C32-B464-D1D5A578AFA6</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a method to culture bronchial epithelial cells obtained from bronchial bushings of normal subjects or those with asthma or COPD. We subsequently refined the protocol to allow for re-differnatition of the cells to recapitulate the in vivo phenotype. We have now extended or protocol to use bronchial brushing obtained by fibreoptic bronchoscopy from paediatric patients undergoing elective surgery (with parental consent).</gtr:description><gtr:id>1BA23414-A311-4680-86B8-296D69073F3C</gtr:id><gtr:impact>This model has allowed us to identify a defective innate immune response by asthmatic and COPD epithelial cells. This has led to a clinical development programme (being undertaken by Synairgen) to test the potential of inhaled interferon beta to reduce or protect against virus-induced asthma exacerbations</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell models</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Synairgen</gtr:companyName><gtr:description>Synairgen is a respiratory drug development company with a particular focus on lung antiviral defence in asthma, COPD and severe viral infections.
www.synairgen.com</gtr:description><gtr:id>2C2AAFE0-EF12-4638-8E40-869CC5235CB4</gtr:id><gtr:impact>Synairgen has developed and progressed inhaled interferon beta for virus-induced asthma exacerbations. The company has just announced positive results in a phase II trial.

2014: Licensing deal with AstraZeneca (http://www.astrazeneca.com/Media/Press-releases/Article/20140612-astrazeneca-inlicenses-sng001)</gtr:impact><gtr:url>http://www.synairgen.com</gtr:url><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/506CD8AA-DE74-4314-8018-F4D18AB85C7F"><gtr:id>506CD8AA-DE74-4314-8018-F4D18AB85C7F</gtr:id><gtr:title>Has the time come to rethink the pathogenesis of asthma?</gtr:title><gtr:parentPublicationTitle>Current opinion in allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13a7699236df16c024620ef8aa26b259"><gtr:id>13a7699236df16c024620ef8aa26b259</gtr:id><gtr:otherNames>Holgate ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/636A13DF-FE69-4D0D-A0BE-8EEDFE9083B8"><gtr:id>636A13DF-FE69-4D0D-A0BE-8EEDFE9083B8</gtr:id><gtr:title>Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9261094ff758ad30fd707b1eebf79713"><gtr:id>9261094ff758ad30fd707b1eebf79713</gtr:id><gtr:otherNames>Papadopoulos NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8151233B-715D-457B-BE21-5474BA14DC11"><gtr:id>8151233B-715D-457B-BE21-5474BA14DC11</gtr:id><gtr:title>Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ebc291e005ab1610b5c2050eb6cb1f3c"><gtr:id>ebc291e005ab1610b5c2050eb6cb1f3c</gtr:id><gtr:otherNames>Calv?n J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/111B6539-4841-426C-98ED-4704E9FFC8DA"><gtr:id>111B6539-4841-426C-98ED-4704E9FFC8DA</gtr:id><gtr:title>The effect of inhaled IFN-? on worsening of asthma symptoms caused by viral infections. A randomized trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d86690ebcc2d5e9359a3cc61c0e832ea"><gtr:id>d86690ebcc2d5e9359a3cc61c0e832ea</gtr:id><gtr:otherNames>Djukanovic R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A2721C6-4552-4D5B-8C50-FE8651DC57C8"><gtr:id>9A2721C6-4552-4D5B-8C50-FE8651DC57C8</gtr:id><gtr:title>A microRNA network dysregulated in asthma controls IL-6 production in bronchial epithelial cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/454bfcc6b86e69fa0e13f05b526dd3e9"><gtr:id>454bfcc6b86e69fa0e13f05b526dd3e9</gtr:id><gtr:otherNames>Martinez-Nunez RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1112875A-5534-4965-9306-08EEC10354C9"><gtr:id>1112875A-5534-4965-9306-08EEC10354C9</gtr:id><gtr:title>The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13a7699236df16c024620ef8aa26b259"><gtr:id>13a7699236df16c024620ef8aa26b259</gtr:id><gtr:otherNames>Holgate ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1546-3222</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69233621-EBDB-4605-B36E-C2EA2251380E"><gtr:id>69233621-EBDB-4605-B36E-C2EA2251380E</gtr:id><gtr:title>Contribution of bronchial fibroblasts to the antiviral response in asthma.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1372d4ee920433b8a2b50cf460d4832"><gtr:id>b1372d4ee920433b8a2b50cf460d4832</gtr:id><gtr:otherNames>Bedke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97CA1766-6E0B-40C3-834A-5CB6A6B45F1C"><gtr:id>97CA1766-6E0B-40C3-834A-5CB6A6B45F1C</gtr:id><gtr:title>Rhinovirus-16 induced release of IP-10 and IL-8 is augmented by Th2 cytokines in a pediatric bronchial epithelial cell model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdf236abadd59c50f2a6319fb59a6457"><gtr:id>bdf236abadd59c50f2a6319fb59a6457</gtr:id><gtr:otherNames>Cakebread JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34558510-F6CD-4FA9-A81B-6E17CACCFEC4"><gtr:id>34558510-F6CD-4FA9-A81B-6E17CACCFEC4</gtr:id><gtr:title>Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1372d4ee920433b8a2b50cf460d4832"><gtr:id>b1372d4ee920433b8a2b50cf460d4832</gtr:id><gtr:otherNames>Bedke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2930C47D-90D5-477D-BBE2-742B48A710D1"><gtr:id>2930C47D-90D5-477D-BBE2-742B48A710D1</gtr:id><gtr:title>The innate antiviral response upregulates IL-13 receptor a2 in bronchial fibroblasts.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c266e75a45719efdd289278d39101679"><gtr:id>c266e75a45719efdd289278d39101679</gtr:id><gtr:otherNames>Campbell-Harding G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED6D3B78-163D-4BB9-912C-924C945B7D6B"><gtr:id>ED6D3B78-163D-4BB9-912C-924C945B7D6B</gtr:id><gtr:title>In vitro and ex vivo models of human asthma.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b9d2cf18d6caad596bebc041d226187"><gtr:id>2b9d2cf18d6caad596bebc041d226187</gtr:id><gtr:otherNames>Blume C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F35E36F-C99E-481A-8982-E0FDE3B5088A"><gtr:id>8F35E36F-C99E-481A-8982-E0FDE3B5088A</gtr:id><gtr:title>Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13a7699236df16c024620ef8aa26b259"><gtr:id>13a7699236df16c024620ef8aa26b259</gtr:id><gtr:otherNames>Holgate ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1A187AE-B2E7-4228-9106-7990E966ABB6"><gtr:id>F1A187AE-B2E7-4228-9106-7990E966ABB6</gtr:id><gtr:title>A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e0139d19d0f91588edb2f39241fbfe1"><gtr:id>3e0139d19d0f91588edb2f39241fbfe1</gtr:id><gtr:otherNames>B?nnelykke K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCA9271A-4C1E-4FEA-9E01-F5FDD844352E"><gtr:id>CCA9271A-4C1E-4FEA-9E01-F5FDD844352E</gtr:id><gtr:title>IFN-gamma-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/541ef7df24afacf76a526214162d622c"><gtr:id>541ef7df24afacf76a526214162d622c</gtr:id><gtr:otherNames>Wark PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3BE2916-1D20-4EE4-B15C-142E325A9151"><gtr:id>F3BE2916-1D20-4EE4-B15C-142E325A9151</gtr:id><gtr:title>Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial cells from donors with asthma.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/95863687bb1f6112d0742a9ecfcfca46"><gtr:id>95863687bb1f6112d0742a9ecfcfca46</gtr:id><gtr:otherNames>Uller L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/930AF0EB-7187-4763-AF04-8043C6990C01"><gtr:id>930AF0EB-7187-4763-AF04-8043C6990C01</gtr:id><gtr:title>The role of the epithelium in airway remodeling in asthma.</gtr:title><gtr:parentPublicationTitle>Proceedings of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c22f80cc8dda3ef4f676f9f68ad44d8"><gtr:id>7c22f80cc8dda3ef4f676f9f68ad44d8</gtr:id><gtr:otherNames>Davies DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1546-3222</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F480BE2F-F576-432C-9D8E-47AD18D1F909"><gtr:id>F480BE2F-F576-432C-9D8E-47AD18D1F909</gtr:id><gtr:title>Epithelium dysfunction in asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/13a7699236df16c024620ef8aa26b259"><gtr:id>13a7699236df16c024620ef8aa26b259</gtr:id><gtr:otherNames>Holgate ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F763064-3D2E-4A51-AA36-C5DACD1C9723"><gtr:id>7F763064-3D2E-4A51-AA36-C5DACD1C9723</gtr:id><gtr:title>Exogenous IFN-? has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdf236abadd59c50f2a6319fb59a6457"><gtr:id>bdf236abadd59c50f2a6319fb59a6457</gtr:id><gtr:otherNames>Cakebread JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28257C2F-3583-4DE1-905B-F9FF2F17BF84"><gtr:id>28257C2F-3583-4DE1-905B-F9FF2F17BF84</gtr:id><gtr:title>Artificial airways for the study of respiratory disease.</gtr:title><gtr:parentPublicationTitle>Expert review of respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b877f0d3bc7441cc979c0e1dfcd3b87"><gtr:id>3b877f0d3bc7441cc979c0e1dfcd3b87</gtr:id><gtr:otherNames>Swindle EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1747-6348</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/288C4561-0F1D-42EF-8BB0-ACA1B56A8BAC"><gtr:id>288C4561-0F1D-42EF-8BB0-ACA1B56A8BAC</gtr:id><gtr:title>Breakdown in epithelial barrier function in patients with asthma: identification of novel therapeutic approaches.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b877f0d3bc7441cc979c0e1dfcd3b87"><gtr:id>3b877f0d3bc7441cc979c0e1dfcd3b87</gtr:id><gtr:otherNames>Swindle EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501506</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>